Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.

Kabore FN, Eymard-Duvernay S, Zoungrana J, Badiou S, Bado G, Héma A, Diouf A, Delaporte E, Koulla-Shiro S, Ciaffi L, Cournil A.

PLoS One. 2017 Nov 8;12(11):e0186686. doi: 10.1371/journal.pone.0186686. eCollection 2017.

2.

Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial.

Cournil A, Hema A, Eymard-Duvernay S, Ciaffi L, Badiou S, Kabore FN, Diouf A, Ayangma L, Le Moing V, Reynes J, Koulla-Shiro S, Delaporte E; 2LADY Study Group.

Antivir Ther. 2017;22(3):195-203. doi: 10.3851/IMP3097. Epub 2016 Oct 5.

PMID:
27705950
3.
4.

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.

Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL.

PLoS One. 2012;7(3):e32445. doi: 10.1371/journal.pone.0032445. Epub 2012 Mar 29.

5.

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M; ASSERT Team.

Antivir Ther. 2013;18(7):905-13. doi: 10.3851/IMP2667. Epub 2013 Jul 31.

PMID:
23899468
6.

Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.

Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X.

J Int AIDS Soc. 2013 Apr 30;16:18059. doi: 10.7448/IAS.16.1.18059.

7.

Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.

Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Sophonphan J, Ananworanich J, Puthanakit T; Bone-D study group.

Antivir Ther. 2017;22(6):471-479. doi: 10.3851/IMP3103. Epub 2016 Oct 27.

PMID:
27786155
8.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.

J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5.

9.

Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.

Cournil A, Eymard-Duvernay S, Diouf A, Moquet C, Coutherut J, Ngom Gueye NF, Cames C, Taverne B, Bork K, Sow PS, Delaporte E; ANRS 1215 Study Group.

PLoS One. 2012;7(2):e31726. doi: 10.1371/journal.pone.0031726. Epub 2012 Feb 16.

10.

Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.

Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM; DAYANA Study Group.

Antivir Ther. 2014;19(1):51-9. doi: 10.3851/IMP2675. Epub 2013 Aug 23.

PMID:
23970206
11.

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, Brinson C, Benson P, Dau L, Wang H, White K, Flaherty J, Fralich T, Guyer B, Piontkowsky D.

Clin Infect Dis. 2013 Jun;56(11):1637-45. doi: 10.1093/cid/cis1203. Epub 2013 Jan 29. Erratum in: Clin Infect Dis. 2013 Sep;57(5):779.

12.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

13.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
15.

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, STEAL Study Group.

PLoS One. 2012;7(6):e38377. doi: 10.1371/journal.pone.0038377. Epub 2012 Jun 15.

16.
17.

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.

Antivir Ther. 2012;17(6):1011-20. doi: 10.3851/IMP2305. Epub 2012 Aug 15.

PMID:
22910324
18.

Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.

Hsieh E, Fraenkel L, Xia W, Hu YY, Han Y, Insogna K, Yin MT, Xie J, Zhu T, Li T.

Osteoporos Int. 2015 Mar;26(3):1035-44. doi: 10.1007/s00198-014-2874-3. Epub 2014 Sep 16.

19.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.

Antivir Ther. 2015;20(3):317-27. doi: 10.3851/IMP2885. Epub 2014 Oct 16.

PMID:
25321623
20.

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS.

HIV Med. 2016 Feb;17(2):106-17. doi: 10.1111/hiv.12281. Epub 2015 Jul 14.

Supplemental Content

Support Center